

ROR γ : THE THIRD MEMBER OF ROR/RZR ORPHAN RECEPTOR SUBFAMILY THAT IS HIGHLY EXPRESSED IN SKELETAL MUSCLE¹

Takahisa Hirose², Robert J. Smith, and Anton M. Jetten³

Cell Biology Section, Laboratory of Pulmonary Pathobiology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709

Received November 17, 1994

In this study, we describe the identification and cloning of a novel member of the nuclear receptor superfamily. This orphan receptor, referred to as ROR γ , belongs to the ROR/RZR subfamily. The open reading frame of ROR γ encodes a protein of 560 amino acid residues with a predicted molecular mass of 63 kD. The amino acid sequence of ROR γ exhibits a 50 and 51% identity with those of ROR α /RZR α and RZR β , respectively, whereas the DNA-binding domains were 89% identical. ROR γ was localized on human chromosome 1. Northern blot analysis using RNA from multiple tissues indicated that ROR γ is expressed in several tissues but is most highly expressed in skeletal muscle. © 1994 Academic Press, Inc.

The nuclear receptor gene superfamily encodes an increasing number of transcriptional regulators that play critical roles during homeostasis and specific stages of development (1,2). Members of this gene family includes the steroid hormone, thyroid hormone and retinoid receptors, and orphan receptors for which a ligand has not yet been identified (3,4). The members of this family share a common modular structure that includes a highly homologous DNA-

¹Sequence data from this article have been deposited with EMBL/GenBank Data Libraries under Accession Number U16997.

²Current address: Department of Medicine III, Osaka University Medical School, Yamadaoka, Suita, Osaka, Japan.

³To whom reprint requests should be addressed. Fax.: 919-541-4133; E-mail: jetten@niehs.nih.gov.

binding domain (DBD) containing two "zinc-finger" motifs. Most of these nuclear receptors bind as monomers (5,6), homodimers and heterodimers to response elements composed of the single half-site motif PuGGTCA preceded by an AT-rich sequence or direct, palindromic or inverted palindromic repeats of the core motif spaced by one or more nucleotides (reviews in 7,8).

Using reverse transcription-PCR and degenerate primers whose designs were based on the two most conserved regions of the DBD of known members of the nuclear receptor superfamily, we identified and cloned a novel orphan receptor, named ROR γ . Based on its overall amino acid homology (50-51%) with ROR α /RZR α and RZR β , this gene encodes the third member of the ROR/RZR subfamily of orphan receptors (6,9,10). Each member of the ROR/RZR subfamily exhibits a different tissue distribution suggesting that they have different functions. ROR γ appears to play a role in controlling gene expression in several tissues and particularly in skeletal muscle.

MATERIALS AND METHODS

PCR amplification - A set of degenerate primers was designed according to the most highly conserved sequence of the DNA-binding domain of members of the nuclear receptor family as previously described (11,12). Single strand complementary DNA reverse transcribed from human pancreas poly(A)⁺ RNA was employed with the primers in the amplification reaction using the Amplitaq kit and a DNA thermal cycler (Perkin-Elmer Cetus). The DNA products of 130bp were isolated from the gel and directly ligated to the TA cloning vector (Invitrogen). The DNA inserts of thirty clones were analyzed by double strand dideoxy DNA sequencing using Sequenase (U.S.Biochemical). One novel DBD sequence was obtained and named ROR γ -DBD.

Anchor PCR - The 5'-RACE kit (BRL) was employed to isolate a greater region of the gene encoding ROR γ (11,12). Briefly, two sequential antisense primers were designed from the sequence of the ROR γ -DBD PCR fragment. Single strand cDNA was synthesized from 1 μ g of human pancreas poly(A)⁺RNA with Superscript reverse transcriptase using the first strand primer according to the manufacturer's recommendation (BRL). Following denaturation by heating, the products were homopolymerically tailed with deoxy-CTP and terminal deoxytransferase and subsequently amplified by PCR at stringent conditions with the anchor primer poly-(dG) and the nested primer. The amplification products were subcloned into pBluescript plasmid (Stratagene) and 3 independent clones sequenced.

cDNA library screening - A λ gt10-phage cDNA library from human skeletal muscle (Clontech) was screened under stringent conditions

with a multiprimed cDNA probe made from the anchor PCR products. cDNA inserts from several positive clones were subcloned into the *EcoRI* site of pBluescript. The complete DNA sequences of both strands were determined by the method described above.

Chromosomal localization - A BIOS Blot Somatic Cell Hybrid Panel was purchased from BIOS Laboratories (New Haven, CT). The blot was made from *TaqI* digested genomic DNA prepared from different human/hamster or human/mouse hybrid cell lines. Each cell line contained in addition to a complete set of hamster or mouse chromosomes one or more human chromosomes. The human chromosomes contained in each hybrid cell line are listed in Fig. 3B. The cell line 016 represents a human/mouse hybrid cell line, all others are human/hamster hybrid cell lines. The blot was hybridized with ³²P-labelled hROR γ probe (nt 1-250) and washed with 0.2x SSC and 0.1% SDS at 65°C.

Northern blot analysis - Human multiple tissue Northern blots were purchased from Clontech. The blots were hybridized with a ³²P-labeled (Amersham) ROR γ probe encoding the nucleotides 1 to 250 as described previously (13).

RESULTS AND DISCUSSION

Cloning of ROR γ cDNA - Highly degenerate primers were designed according to the two best conserved amino acid sequences present in the DBD of members of the nuclear receptor family. These primers were then employed in amplification reactions with single strand cDNA from human pancreas poly(A)⁺ RNA in order to identify DBD's of novel nuclear receptors. The amplified fragments of the expected size (130 bp) were cloned in TA vector and 30 clones sequenced. Most of the cDNA sequences encoded DBD's of known receptors including those of RAR α (14,15) and RXR β (16). Among these cDNAs, we identified one which encoded a unique sequence not previously described. The amino acid residues predicted by this cDNA sequence suggested that it encoded the DBD of a novel member of the nuclear receptor superfamily which we refer to as ROR γ . With the help of the 5'-RACE method we obtained a 400 bp fragment of the ROR γ gene that was subsequently used as a probe in screening a human skeletal muscle cDNA library. After screening 9 x 10⁵ independent plaques, three positive clones were obtained which combined included almost the full length coding region of ROR γ . Analysis of this ROR γ sequence revealed a long open reading frame which starts with a putative initiation codon at nucleotide 70 and terminates with a putative stop codon at 1750 (Fig. 1). On this basis, ROR γ encodes a protein of 560 amino acid residues with a predicted molecular weight of 62.6 kilodaltons. Fig. 2A shows the amino acid comparison of ROR γ and

CCCCTGGGCCCTGCTCCCTGCCCTCTGGGCAGCCAGGGCAGCCAGGACGGCACCAAGGGAGCTGCCCC																												69														
ATG	GAC	AGG	GCC	CCA	CAG	AGA	CAG	CAC	CGA	GCC	TCA	CGG	GAG	CTG	CTG	GCT	GCA	AAG	AAG	129	Met	Asp	Arg	Ala	Pro	Gln	Arg	Gln	His	Arg	Ala	Ser	Arg	Glu	Leu	Leu	Ala	Ala	Lys	Lys	20	
ACC	CAC	ACC	TCA	CAA	ATT	GAA	GTG	ATC	CCT	TGC	AAA	ATC	TGT	GGG	GAC	AAG	TCG	TCT	GGG	189	Thr	His	Thr	Ser	Gln	Ile	Val	Ile	Pro	Cys	Lys	Ile	Cys	Gly	Asp	Lys	Ser	Ser	Gly	40		
ATC	CAC	TAC	GGG	GTT	ATC	ACC	TGT	GAG	GGG	TGC	AAG	GGC	TTC	TTC	CGC	CGG	AGC	CAG	CGC	249	Ile	His	Tyr	Gly	Val	Ile	Thr	Cys	Glu	Gly	Cys	Lys	Gly	Phe	Phe	Arg	Arg	Ser	Gln	Arg	60	
TGT	AAC	GCG	GCC	TAC	TCC	TGC	ACC	CGT	CAG	CAG	AAC	TGC	CCC	ATC	GAC	CGC	ACC	AGC	CGA	309	Cys	Asn	Ala	Ala	Tyr	Ser	Cys	Thr	Arg	Gln	Gln	Asn	Cys	Pro	Ile	Asp	Arg	Thr	Ser	Arg	80	
AAC	CGA	TGC	CAG	CAC	TGC	CGC	CTG	CAG	AAA	TGC	CTG	GCG	CTG	GGG	ATG	TCC	GAT	GCT	369	Asn	Arg	Cys	Gln	His	Cys	Arg	Leu	Gln	Lys	Cys	Leu	Ala	Leu	Gly	Met	Ser	Arg	Asp	Ala	100		
GTC	AAG	TTC	GGC	CGC	ATG	TCC	AAG	AAG	CAG	AGG	GAC	AGC	CTG	CAT	GCA	GAA	GTG	CAG	AAA	429	Val	Lys	Phe	Gly	Arg	Met	Ser	Lys	Lys	Gln	Arg	Asp	Ser	Leu	His	Ala	Glu	Val	Gln	Lys	120	
CAG	CTG	CAG	Gln	Arg	CAA	CAG	CAA	CAG	GAA	CCA	GTG	GTC	AAG	ACC	CCT	CCA	GCA	GGG	489	Gln	Leu	Gln	Gln	Gln	Gln	Gln	Gln	Glu	Pro	Val	Val	Lys	Thr	Pro	Ala	Gly	140					
GCC	CAA	GGA	GCA	GAT	ACC	CTC	ACC	TAC	ACC	TTG	GGG	CTC	CCA	GAC	GGG	CAG	CTG	CCC	CTG	549	Ala	Gln	Gly	Ala	Asp	Thr	Leu	Thr	Tyr	Thr	Leu	Gly	Leu	Pro	Asp	Gly	Gln	Leu	Pro	Leu	160	
GGC	TCC	TCG	CCT	GAC	CTG	CCT	GAG	GCT	TCT	GCC	TGT	CCC	CCT	GGC	CTC	CTG	AAA	GCC	TCA	609	Gly	Ser	Ser	Pro	Asp	Leu	Pro	Glu	Ala	Leu	Cys	Pro	Pro	Gly	Leu	Leu	Ala	GCC	TCA	Gly	Ser	180
GGC	TCT	GGG	CCC	TCA	TAT	TCC	AAC	AAC	TTG	GCC	AAG	GCA	GGG	CTC	AAT	GGG	GCC	TCA	TGC	669	Gly	Ser	Gly	Pro	Ser	Tyr	Ser	Asn	Asn	Leu	Ala	Lys	Ala	Gly	Leu	Asn	Gly	Ala	Ser	Cys	200	
CAC	CTT	GAA	TAC	AGC	CCT	GAG	CGG	GGC	AAG	GCT	GAG	GGC	AGA	GAG	AGC	TTC	TAT	AGC	ACA	729	His	Leu	Glu	Tyr	Ser	Pro	Glu	Arg	Gly	Lys	Ala	Glu	Gly	Arg	Glu	Ser	Asn	His	Thr	220		
GGC	AGC	CAG	CTG	ACC	CCT	GAC	CGA	TGT	GGA	CTT	CGT	TTT	GAG	GAA	CAC	AGG	CAT	CCT	GGG	789	Gly	Ser	Gln	Leu	Thr	Pro	Asp	Arg	Cys	Gly	Leu	Arg	Phe	Glu	Glu	His	Arg	His	Pro	Gly	240	
CTT	GGG	GAA	CTG	GGA	CAG	GGC	CCA	GAC	AGC	TAC	GGC	AGC	CCC	AGT	TTC	CGC	AGC	ACA	CGG	849	Leu	Gly	Glu	Leu	Gly	Gln	Gly	Pro	Ser	Tyr	Gly	Ser	Pro	Ser	Phe	Arg	Arg	Thr	Pro	260		
GAG	GCA	CCC	TAT	GCC	TCC	CTG	ACA	GAG	ATA	GAG	CAC	CTG	GTG	CAG	AGC	GTC	TGC	AAG	TCC	909	Glu	Ala	Pro	Tyr	Ala	Ser	Leu	Thr	Glu	Ile	Glu	His	Leu	Val	Gln	Ser	Val	Cys	Lys	Ser	280	
TAC	AGG	GAG	ACA	TGC	CAG	CTG	CGG	CTG	GAG	GAC	CTG	CTG	CGG	CAG	CGC	TCC	AAC	ATC	TTC	969	Tyr	Arg	Glu	Thr	Cys	Gln	Leu	Arg	Leu	Leu	Arg	Gln	Arg	Ser	Asn	His	Phe	300				
TCC	CGG	GAG	GAA	GTG	ACT	GGC	CAG	AGG	AAG	TCC	ATG	TGG	GAG	ATG	TGG	GAA	CGG	TGT	1029	Ser	Arg	Glu	Glu	Val	Thr	Gly	Tyr	Gln	Arg	Lys	Ser	Met	Trp	Glu	Met	Trp	Glu	Arg	Cys	320		
GCC	CAC	CAC	CTC	ACC	GAG	GCC	ATT	CAG	TAC	GTG	GTG	GAG	TTC	GCC	AAG	AGG	CTC	TCA	GGC	1089	Ala	His	His	Leu	Thr	Gln	Leu	Ala	Ile	Val	Val	Glu	Phe	Ala	Lys	Arg	Leu	Ser	Gly	340		
TTT	ATG	GAG	CTC	TGC	CAG	AAT	GAC	CAG	ATT	GTG	CTT	CTC	AAA	GCA	GGA	GCA	ATG	GAA	GTG	1149	Phe	Met	Glu	Leu	Cys	Gln	Asn	Asp	Gln	Ile	Val	Leu	Leu	Lys	Ala	Gly	Ala	Met	Glu	Val	360	
GTG	CTG	GTT	AGG	ATG	TGC	CGG	GCC	TAC	AAT	GCT	GAC	AAC	CGC	ACG	GTC	TTT	TTT	GAA	GGC	1209	Val	Leu	Val	Arg	Met	Cys	Arg	Ala	Tyr	Asn	Ala	Asp	Asn	Arg	Thr	Val	Phe	Glu	Gly	380		
AAA	TAC	GGT	GGC	ATG	GAG	CTG	TTC	CGA	GCC	TTG	GGC	TGC	AGC	GAG	CTC	ATC	AGC	TCC	ATC	1269	Lys	Tyr	Gly	Gly	Met	Glu	Leu	Phe	Arg	Ala	Leu	Gly	Cys	Ser	Glu	Leu	Ile	Ser	Ser	Ile	400	
TTT	GAC	TTC	TCC	CAC	TCC	CTA	AGT	GGC	TTG	CAC	TTT	TCC	GAG	GAT	GAG	ATT	GCC	CTC	TAC	1329	Phe	Asp	Phe	Ser	His	Leu	Ser	Ala	Leu	His	Phe	Ser	Glu	Asp	Glu	Ile	Ala	Leu	Tyr	420		
ACA	GCC	CTT	GTT	CTC	ATC	AAT	GCC	CAT	CGG	CCA	GGG	CTC	CAA	GAG	AAA	AGG	AAA	GTA	GAA	1389	Thr	Ala	Leu	Val	Leu	Ile	Asn	Ala	His	Arg	Pro	Gly	Leu	Gln	Glu	Lys	Arg	Lys	Val	Glu	440	
CAG	CTG	CAG	TAC	AAT	CTG	GAG	CTG	GCC	TTT	CAT	CAT	CAT	CTC	TGC	AAG	ACT	CAT	CGC	CAA	1449	Gln	Leu	Gln	Tyr	Asn	Leu	Glu	Leu	Ala	Phe	His	His	His	Leu	Cys	Lys	Thr	His	Arg	Gln	460	
AGC	ATC	CTG	GCA	AAG	CTG	CCA	CCC	AAG	GGG	AAG	CTT	CGG	AGC	CTG	TGT	AGC	CAG	CAT	GTG	1509	Ser	Ile	Leu	Ala	Lys	Leu	Pro	Pro	Lys	Gly	Lys	Leu	Arg	Ser	Leu	Cys	Ser	Gln	His	Val	480	
GAA	AGG	CTG	CAG	ATC	TTC	CAG	CAC	CTC	CAC	CCC	ATC	GTG	GTC	CAA	GCC	GCT	TTC	CCT	CCA	1569	Glu	Arg	Leu	Gln	Ile	Phe	Gln	His	Leu	His	Pro	Ile	Val	Val	Gln	Ala	Ala	Phe	Pro	Pro	500	
CTC	TAC	AAG	GAG	CTC	TTC	AGC	ACT	GAA	ACC	GAG	TCA	CCT	GTG	GGC	TGT	CCA	AGT	GAC	CTG	1629	Leu	Tyr	Lys	Glu	Leu	Phe	Ser	Thr	Glu	Thr	Glu	Ser	Pro	Val	Gly	Cys	Pro	Ser	Asp	Leu	520	
GAA	GAG	GGA	CTC	CTT	GCC	TCT	CCC	TAT	GGC	CTG	CTG	GCC	ACC	TCC	CTG	GAC	CCC	GTT	CCA	1689	Glu	Glu	Gly	Leu	Leu	Ala	Ser	Pro	Tyr	Gly	Leu	Leu	Ala	Thr	Ser	Leu	Glu	Pro	Val	Pro	540	
CCC	TCA	CCC	TTT	TCC	TTT	CCC	ATG	AAC	CCT	GGA	GGG	TGG	TCC	CCA	CCA	GCT	CTT	TGG	AAG	1749	Pro	Ser	Pro	Phe	Ser	Phe	Pro	Met	Asn	Pro	Gly	Gly	Trp	Ser	Pro	Ala	Leu	Trp	Lys	560		
TGA*GCAGATGCTGCGGCTGGCTTTCTGTGTCAGCAGGCCGCGCTGGCAGTGGGACAAATCGCCAGAGGGTGGG																												1819														

Fig. 1. Nucleotide and deduced amino acid sequence of RORY. Nucleotides and amino acids are numbered on the right side of the sequence. The putative initiation codon is at nt 70. The DNA-binding domain and putative ligand binding domain are underlined. The termination codon (nt 1750) at the end of RORY amino acid sequence is indicated as *.




Fig. 2. Comparison between the amino acid sequence of hROR γ and several other members of the nuclear receptor family. **A.** Alignment of the amino acid sequences of the DBD's and ligand-binding domains. The numbers in each box indicate the percentage of identity with hROR γ . The DBD and ligand-binding domain are indicated. **B.** Comparison between the amino acid sequence of the DBD, P-, T- and A-box of ROR γ , ROR/RZR α , RZR β , Rev-erb β , RAR α and RXR α . Specific references are ROR/RZR α (6,9), RZR β (10), Rev-erb β (17), RAR α (14,15) and RXR α (18). The prefix h, m, and r denotes human, mouse, and rat, respectively. * indicates gap.

several other nuclear receptors. The amino acid sequence of ROR γ was most homologous (respectively, 51 and 50% identity) to that of hRZR α /ROR α and rRZR β (6,9,10) with the highest identity (89 and 91%) in the DBD. The DBD of ROR γ exhibits a much lower homology with those of other nuclear receptors such as hRAR α and mRev-erb β (64 and 63% identity, respectively)(14,15,17). These results suggest that ROR γ is a novel member of the ROR/RZR orphan receptor subfamily. High homology was observed between the T-box of ROR γ and those of hRZR α /ROR α , rRZR β and Rev-erb β (Fig. 2B). The T-box is a critical determinant in receptor binding to nucleotides extending 5' of the core-binding site PuGGTCA and may indicate that ROR γ binds to similar response elements as Rev-erb β and the other ROR's (Fig. 2B)(5,17).




Fig. 4. Tissue distribution of ROR γ mRNA. Poly(A)⁺RNA (2 μ g) isolated from different human tissues was analyzed by Northern blot analysis using a [³²P]-labeled ROR γ probe. RNA size markers are indicated between the two blots.

21. Since only chromosome 1 and 5 are common to these cell lines and in contrast to chromosome 5 no other cell line contained human chromosome 1 (Fig. 3B), it was concluded that the ROR γ gene is located on human chromosome 1.

Tissue-specific expression of ROR γ - To study the tissue-specific expression of ROR γ mRNA, we performed Northern blot analysis on poly(A)⁺ RNA prepared from a variety of human tissues (Fig.4). ROR γ was expressed in several tissues, predominantly as a 3.2 kb mRNA. This ROR γ mRNA was most highly expressed in skeletal muscle and at moderate levels in the thymus where the ROR γ probe in addition to the 3.2 kb transcript hybridized to two other transcripts of 7.2 and 5.2 kb. ROR γ was expressed at low levels in the pancreas, the tissue from which the original ROR γ -DBD fragment was cloned, and in the prostate, testis, heart and liver. The size of the transcripts to which ROR γ hybridizes as well as the tissue distribution of ROR γ is different from those of ROR α /RZR α and RZR β (6,9,10). ROR α /RZR α is expressed ubiquitously with highest abundance in peripheral blood leukocytes as transcripts of different size (mainly 15kb and 2.4kb)(9). RZR β appears to be uniquely expressed in the brain as transcripts of 10kb and 2.4kb (10). These differences in tissue distribution suggest that each ROR/RZR receptor has a different function and regulates gene expression of different biological processes.

REFERENCES

1. Evans, R. M. (1988) *Science*, 240, 889-895.
2. Green, S., & Chambon, P. (1988) *Trends. Genet.*, 4, 309-314.
3. Laudet, V., Hanni, C., Coll, J., Catzeflis, F., & Stehelin, D. (1992) *EMBO J.*, 11, 1003-1013.
4. O'Malley, B. W., & Conneely, O. M. (1992) *Mol. Endocrinol.*, 6, 1359-1361.
5. Wilson, T. E., Fahrner, T. J., & Milbrandt, J. (1993) *Mol. Cell. Biol.*, 13, 5794-5804.
6. Giguere, V., Tini, M., Flock, G., Ong, E., Evans, R. M., & Otulakowski, G. (1994) *Genes Dev.*, 8, 538-553.
7. Glass, C.K. (1994) *Endocrine Reviews*, 15, 391-407.
8. Giguere, V. (1994) *Endocrine Reviews*, 15, 61-795.
9. Becker-Andre, M., Andre, E., and DeLamarter, J. F. (1993) *Biochem. Biophys. Res. Commun.*, 194, 1371-1379.
10. Carlberg, C., van Huijsduijnen, R. H., Staple, J. K., DeLamarter, J. F., & Becker-Andre, M. (1994) *Mol. Endocrinol.*, 8, 757-770.
11. Hirose, T., Fujimoto, W., Yamaai, T., Kim K. H., Matsuura, H. & Jetten, A. M. (1994) *Mol. Endocrinol.*, 8, in press.
12. Hirose, T., O'Brien, D. A., & Jetten, A. M. (1994) *Gene* in press.
13. Hirose, T., Koga, M., Kouhara, H., Kishimoto, S., Matsumoto, K. & Sato, B. (1990) *Cancer. Res.*, 50, 5060-5064.
14. Petkovich, M., Brand, N. J., Krust, A., and Chambon, P. (1987) *Nature*, 330, 444-450.
15. Giguere, V., Ong, E. S., Segui, P. and Evans, R. M. (1987) *Nature*, 330, 624-629.
16. Yu, V. C., Delsert, C. Anderson, B., Holloway J. M., Devary, O. V., Naar, A. M., Kim, S. Y., Boutin, J. M., Glass, C. K., & Rosenfeld, M. G. (1991) *Cell*, 67, 1251-1266.
17. Forman, B. C., Chen, J., Blumberg, B., Kliewer, S. A., Henshaw, R., Ong, E. S., and Evans, R. M. (1994) *Mol. Endocrinol.*, 8, 1253-1261.
18. Mangelsdorf, D. J., Ong, E. S., Dyck, J. A., & Evans, R. M. (1990) *Nature*, 345, 224-229.